AZD8848 / Sumitomo Pharma, AstraZeneca - LARVOL DELTA

DSP-3025 A Phase 1 Study of Healthy Male Volunteers (clinicaltrials.gov) - P=N/A | N=24 | Completed | Sponsor: Sumitomo Pharma Co., Ltd. | Phase classification: P1 ➔ P=N/A

Phase classification

Effects of the Toll-like receptor 7 (TLR7) agonist, AZD8848, on allergen-induced responses in patients with mild asthma: a double-blind, randomised, parallel-group study. (PubMed, Respir Res) - P2a | "In patients with allergic asthma, TLR7 agonists could potentially reduce allergen responsiveness by stimulating Type 1 interferon responses to down-regulate the dominant Th2 responses."

Clinical • Journal • Allergy • Asthma • Immunology • Respiratory Diseases

R&D meeting (Dainippon Sumitomo Press Release) - Anticipated launch in Japan for asthma after 2018.

Anticipated launch Japan • Asthma

To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses AZD8848 in Healthy Subjects (clinicaltrials.gov) - P1; N=24; Suspended; Sponsor: AstraZeneca; Recruiting -> Suspended

Trial suspension • Acute Coronary Syndrome • Biosimilar • Chronic Kidney Disease • Heart Failure • Hepatitis C Virus • Immunology • Myositis • Pain

Astrazeneca development pipeline, 30 September 2014 (AstraZeneca Press Release) - Product development discontinued for asthma.

Discontinued • Asthma

The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen (clinicaltrials.gov) - P2a; N=61; Completed; Sponsor: AstraZeneca; Active, not recruiting ➔ Completed

Clinical • Trial completion